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Summary
Polo-like kinases (PLKs) play critical roles throughout
mitosis. Here, we report that wortmannin, which was
previously thought to be a highly selective inhibitor
of phosphoinositide (PI) 3-kinases, is a potent inhi-
bitor of mammalian PLK1. Observation of the wort-
mannin-PLK1 interaction was enabled by a tetra-
methylrhodamine-wortmannin conjugate (AX7503) that
permits rapid detection of PLK1 activity and expres-
sion in complex proteomes. Importantly, we show that
wortmannin inhibits PLK1 activity in an in vitro kinase
assay with an IC50 of 24 nM and when incubated with
intact cells. Taken together, our results indicate that,
at the concentrations of wortmannin commonly used
to inhibit PI 3-kinases, PLK1 is also significantly in-
hibited.
Introduction
Polo-like kinases (PLKs) play many important roles dur-
ing mitosis, as they are involved in the activation of
cyclin B/Cdc2 through Cdc25C phosphatase [1–4],
chromosome separation [5–8], centrosome maturation
[8–10], bipolar spindle assembly [6, 10], regulation of
the anaphase-promoting complex [11, 12], and execu-
tion of cytokinesis [13, 14]. Expression of PLK protein
is restricted to proliferating cells, and PLK protein levels
are regulated during the cell cycle. In mammalian cells,
the PLK1 mRNA level is low in G1/S, starts to rise in
G2, reaches maximal in mitosis, and then drops to the
low basal level seen in G1 phase [15, 16]. In addition to
this transcriptional control, the kinase activity of PLK is
also regulated during the cell cycle. Mammalian PLK1
activity is stimulated by phosphorylation on threonine
210 [17].
Human PLK1 has been shown to be overexpressed
in various human cancers, including head and neck
squamous cell carcinomas, non-small cell lung cancer,
oropharyngeal carcinomas, melanomas, ovarian and
endometrial carcinomas, and prostate cancer [18–21].
Consequently, PLK1 has been proposed as a diagnos-
tic marker for several different types of cancers [18–21].
Additionally, constitutive expression of PLK1 is able to
transform mouse NIH-3T3 cells and induces tumor*Correspondence: yongshengl@activx.comgrowth in nude mice [22]. Recent studies with small in-
terfering RNA (siRNA) demonstrated that PLK1 deple-
tion caused cell cycle arrest at mitosis and induced
apoptosis in several cancer cell lines [23]. Therefore,
PLK1 is a possible therapeutic target for the treatment
of human cancer.
A chemical proteomic method, referred to as activity-
based protein profiling (ABPP), that utilizes active site-
directed probes to monitor the functional state of enzyme
families in complex proteomes has been developed
[24–26]. This approach can be contrasted with conven-
tional proteomics, for example, two-dimensional gel
electrophoresis (2DE) coupled with protein staining and
mass spectrometry (MS), which are restricted to re-
cording variations in protein abundance [26]. To date,
activity-based probes (ABPs) that target serine hy-
drolases [24, 27, 28], cysteine proteases [29–31], ser-
ine-threonine phosphatases [32], metalloproteases
[33], as well as several metabolic enzymes, including
dehydrogenases [25], sugar kinases, and glutathione
S-transferases [34, 35] have been successfully gen-
erated.
Jessani and colleagues utilized ABPs that target ser-
ine hydrolases to identify several secreted and mem-
brane-associated enzyme activities upregulated in in-
vasive breast and melanoma cancer cells, including the
secreted protease urokinase, and novel enzymes, like
the membrane-associated hydrolase KIAA1363 [36].
More recently, Greenbaum and colleagues utilized
ABPs that target cysteine proteases to identify falcipain
1 as a protease that is uniquely active in the invasive
merozoite stage of Plasmodium falciparum, the human
malaria parasite [37]. To support falcipain 1 as a target
for antimalarial drugs, the authors showed that falci-
pain 1 inhibitors, identified by utilizing ABPP methods,
strongly inhibited parasite invasion of host erythro-
cytes. Collectively, these findings demonstrate that
ABPP methods provide a powerful tool for discovering
enzymes associated with human disease and chemical
inhibitors that target these enzymes by the screening
of compounds.
We report here the chemical synthesis and utility of
a tetramethylrhodamine-wortmannin conjugate ABP,
AX7503. Wortmannin has been reported to be a highly
selective inhibitor of PI 3-kinase and PI 3-kinase-
related kinases, such as ATM, ATR, and the catalytic
subunit of DNA-dependent protein kinase (DNA-PKcs)
[38–40]. The IC50 of wortmannin for PI 3-kinase is 4.2
nM [38]. Surprisingly, AX7503 was found to label PLK1
in addition to members of the PI 3-kinase superfamily
in complex proteomes. We show for the first time, to
our knowledge, that wortmannin and LY294002, com-
pounds previously thought to be highly selective inhibi-
tors of PI 3-kinases, also inhibit PLK1. In addition, we
show that wortmannin potently inhibits PLK1 activity in
an in vitro kinase assay and inhibits AX7503 labeling of
PLK1 when incubated with intact G2/M-arrested cells.
Finally, we highlight the utility of AX7503 as a probe for
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rcrude cellular extracts.
t
wResults and Discussion
A
Synthesis of the AX7503 Probe
In order to study the PI 3-kinase superfamily of en- C
Tzymes and identify other potential target enzymes in-
hibited by wortmannin in complex proteomes, we syn- s
othesized a tetramethylrhodamine (TAMRA)-wortmannin
conjugate, AX7503 (Figure 1). The TAMRA tag permits w
rboth visualization and purification of proteins modified
by AX7503. Briefly, the synthesis of AX7503 started with l
2the rearrangement of wortmannin to 11-O-desacetyl-
wortmannin (compound 1). Using a modification of the b
nHaefliger synthesis [41], wortmannin was treated with
diethylamine (30 equiv.) in dichloromethane overnight A
pto yield crude 11-O-desacetyl-20-(N,N-diethylimino)-
20-desoxowortmannin. After removal of solvent, this L
(material was treated with 20% 1 N HCl/dioxane, which
resulted in reclosure of the furan ring. Purification with h
bsilica gel chromatography yielded compound 1 in 78%
yield. Importantly, modification of the 11-hydroxyl func- p
Ationality of compound 1 through esterification with
long-chain acids or conjugation to polymers has been 4
(shown to result in analogs with minimal changes in po-
tency against PI 3-kinase when compared to wortman- e
snin [42, 43]. The lack of sensitivity to modification at
this position is explained by the crystal structure of the m
(wortmannin-porcine PI3Kγ complex, in which the 11-
acetoxy group of wortmannin is directed away from the e
mactive site into solvent [38]. Consequently, conjugation
of TAMRA through the 11-OH position was expected to f
lresult in a potent probe not only for PI 3-kinase, but
also for the other wortmannin-reactive members of the t
(PI 3-kinase family. The requisite long-chain TAMRA de-
rivative 2 was synthesized in a two-step, one-pot pro- a
wcedure. Treatment of the succinimidyl active ester of
TAMRA with tetraethyleneglycol diamine, followed by w
Athe addition of succinic anhydride, resulted in the de-Figure 1. Synthesis of AX7503ired product, which was readily separated from impu-
ities by using C18 reverse-phase chromatography. Es-
erification of the alcohol 1 with the carboxylic acid 2
as accomplished by using DIC/DMAP in DCM to yield
X7503 in 31% isolated yield.
haracterization of AX7503
o test the reactivity of AX7503 with the PI 3-kinase
uperfamily of enzymes, we incubated soluble fractions
f Jurkat cells with this probe at 50 nM for 60 min, after
hich the fluorescently labeled proteins were sepa-
ated by SDS-PAGE and visualized in-gel with a flatbed
aser-induced fluorescence scanner. As seen in Figure
A, AX7503 specifically labeled more than five protein
ands (I, II, and III). The labeling of these proteins, but
ot several that may be labeled nonspecifically by
X7503, was blocked when the soluble fractions were
reincubated with 0.5 M wortmannin or 50 M
Y294002 for 10 min prior to treatment with the probe
Figure 2A). When enzymatic activity was abolished by
eat denaturation, AX7503 did not label the proteins in
ands I, II, and III (data not shown). Affinity isolation of
robe-labeled proteins by virtue of the TAMRA tag of
X7503 and mass spectrometric analysis identified the
65 kDa protein (I) as a catalytic subunit of DNA-PK
gi|13654237, 20 peptides matched, 6% sequence cov-
rage), the 110–125 kDa proteins (II) as the catalytic
ubunits of the PI 3-kinase α (gi|1763626, 23 peptides
atched, 22% sequence coverage), the PI 3-kinase β
gi|5453894, 16 peptides matched, 14% sequence cov-
rage), and the PI 3-kinase γ (gi|12620871, 4 peptides
atched, 5% sequence coverage). These results con-
irmed that AX7503 performed as designed to cova-
ently label the PI 3-kinase superfamily. Interestingly,
he 68 kDa protein (III) was identified as PLK1
gi|393017, 5 peptides matched, 13% sequence cover-
ge), which shares no significant sequence identity
ith the PI 3-kinase superfamily. Western blot analysis
ith a monoclonal PLK1 antibody confirmed that
X7503-labeled proteins immuprecipitated via the rho-
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Proteins
(A) Jurkat cells were grown in RPMI medium
1640 containing 10% fetal calf serum in a hu-
mid atmosphere of 5% CO2 at 37°C, and sol-
uble proteome (1.5 mg/ml) derived from
these cells was preincubated with or without
wortmannin (0.5 M) or LY294002 (50 M) for
10 min and then treated with AX7503 (50 nM)
for 60 min. Reactions were quenched with
standard 2× SDS/PAGE loading buffer (re-
ducing), separated by SDS/PAGE, and visu-
alized in-gel with a flatbed laser-induced flu-
orescence scanner (MiraBio).
(B) The scanned gel from (A) was transferred
to nitrocellulose and immunoblotted with
anti-PLK1.
(C) Five breast cancer cell lines were grown to 80% confluence in RPMI medium 1640 containing 10% fetal calf serum in a humid atmosphere
of 5% CO2 at 37°C, and soluble proteome (1.5 mg/ml) derived from these cells was preincubated with or without wortmannin (0.5 M) for 10
min and then treated with AX7503 (50 nM) for 60 min. Reactions were quenched with standard 2× SDS/PAGE loading buffer (reducing),
separated by SDS/PAGE, and visualized in-gel with a flatbed laser-induced fluorescence scanner (MiraBio).damine tag contained the 68 kDa PLK1 (data not shown).
Importantly, PLK1 was not labeled by AX7503 in extracts
preincubated with wortmannin and LY294002 (Figure 2A)
even though the protein is clearly present (Figure 2B).
These results demonstrated that AX7503 was not only
an effective probe for the PI 3-kinase superfamily, but
for PLK1 as well. These findings emphasize that en-
zymes with no sequence similarity may have related
active site structures and that ABPP can be used to
discover such relatedness [25].
Human PLK1 has been shown to be highly expressed
in various human cancers. We selected a panel of hu-
man breast cancer cell lines for analysis with AX7503.
As seen in Figure 2C, AX7503 specifically labeled PLK1
in addition to PI 3-kinases and DNA-PKcs from all five
breast cancer cell lines. The labeling of these proteins
by AX7503 was potently inhibited when the soluble
fractions from MCF-7 and the other cell lines were pre-
incubated with 0.5 M wortmannin for 10 min prior to
treatment with the probe (Figure 2C and data not
shown). Also, these cell lines expressed PLK1 at similar
levels. These results indicated that AX7503 can be used
to label and compare the expression levels of PLK1
from different cell lines and tissues.
To test whether AX7503 is an activity-dependent
probe for PLK1, we transfected constructs encoding
both wild-type PLK1 and the catalytically inactive mu-
tant PLK1 (K82R) into HEK-293 cells [44]. As seen in
Figure 3A, treatment of the soluble fractions of these
cells with AX7503 resulted in the intense labeling of
PLK1 in wild-type PLK1-transfected cells, but only
weak labeling of PLK1 in the mutant PLK1-transfected
cells. The weak labeling of PLK1 in the mutant-contain-
ing cells was consistent with that seen for control cells
transfected with empty vector as well as untransfected
cells. Thus, the weak labeling of PLK1 in the mutant-
containing cells likely represents endogenous levels of
PLK1 in this cell type. Western blot analysis with a
monoclonal PLK1 antibody identified comparable
levels of overexpression for both wild-type and mutant
PLK1 (Figure 3B). These results demonstrated that
AX7503 exclusively reacted with the catalytically activeting the dose-response data in Figure 3A, wortmannin’s
Figure 3. AX7503 Reacts with PLK1 in an Activity-Dependent
Manner
(A) Soluble proteome (1.5 mg/ml) from parental HEK-293 cells and
cells transfected with empty vector (Mock), a wild-type PLK1 con-
struct, and the mutant K82R PLK1 construct was treated with
AX7503 (50 nM) for 60 min. Reactions were quenched with stan-
dard 2× SDS/PAGE loading buffer (reducing), separated by SDS/
PAGE, and visualized in-gel with a flatbed laser-induced fluores-
cence scanner (MiraBio).
(B) The scanned gel from (A) was transferred to nitrocellulose and
immunoblotted with anti-PLK1.form of the enzyme. Since PLK1 activity is regulated
by phosphorylation, we treated recombinant PLK1 with
purified protein phosphatase 2A (PP2A), as PP2A treat-
ment of PLK1 has been shown to decrease the rate
of PLK1-mediated phosphorylation of casein [15]. The
dephosphorylated PLK1 was labeled by AX7503 at a
similar rate to nondephosphorylated PLK1 (data not
shown). These results are consistent with previous re-
ports that the phosphorylation is not required for activ-
ity and serve to highlight potential kinetic differences
between single turnover and multiple turnover reac-
tions [15].
To determine the potency of wortmannin and
LY294002 as inhibitors of PLK1, we quantified competi-
tion between AX7503 and either wortmaninn or
LY294002 for kinases in Jurkat-soluble fractions. By fit-
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ato be 5.8 nM, whereas LY294002’s IC50 value was deter-
mined to be 2.1 M. Wortmannin and LY294002 inhib- o
aited PI 3-kinases with similar potency to their inhibition
of PLK1; their IC50 values for PI 3-kinases were 2.1 nM t
cand 5.3 M, respectively (Figure 4A).
To obtain independent evidence for the ability of t
Pwortmannin to inhibit PLK1, we performed an in vitro
kinase assay for the ability of pure PLK1 to phosphoryl-
iate a recombinant substrate. As seen in Figure 4B,
PLK1 activity was inhibited by wortmannin with an IC50 a
cvalue of 24 nM, consistent with the results obtained
from Figure 4A. Using the same assay, we also found c
wthat AX7503 inhibited PLK1 with similar potency to
wortmannin itself (data not shown). Further, LY294002 l
linhibited PLK1 in the in vitro kinase assay with similar
potency to its inhibition of AX7503 labeling of PLK1 o
A(data not shown).
J
aIn Vivo Inhibition of PLK1 by Wortmannin
iThe level and activity of PLK are regulated during the
mcell cycle. In mammalian cells, PLK1 protein levels are
alow in G1 and S phase but start to rise in G2 and reach
imaximal in mitosis [45, 46]. To test whether AX7503
ccould be used to observe cell cycle-dependent
bchanges in PLK1 protein levels in crude cellular ex-
ftracts, we chemically synchronized Jurkat cells at
ueither G1/S or G2/M. As seen in Figure 5A, AX7503 la-
Tbeled PLK1 strongly in the soluble fraction of the G2/
M-arrested cells, but only labeled PLK1 weakly in the cFigure 4. Wortmannin and LY294002 Are Inhibitors of PLK1
(A) Dose-response curves of wortmannin and LY294002 for AX7503 labeling of PLK1 and PI 3-kinases. Jurkat-soluble fractions were treated
with AX7503 (50 nM) for 60 min with or without preincubation with various concentrations of wortmannin (0.25–50 nM) or LY294002 (10–
50,000 nM) for 10 min. Reactions were quenched with standard 2× SDS/PAGE loading buffer (reducing), separated by SDS/PAGE, and
visualized in-gel with a flatbed laser-induced fluorescence scanner (MiraBio). Fluorescently labeled PLK1 and PI
3-kinases were quantified by measuring integrated band intensities (normalized for volume); control samples (DMSO alone) were considered
to have 100% activity, and wortmannin and LY 294002-treated samples were expressed as a percentage of remaining activity. IC50 values
were determined from dose-response curves by using Prism software (GraphPad). Open square, PLK1-wortmannin; open triangle, PLK1-
LY294002; closed triangle, PI 3-kinase-wortmannin; closed diamond, PI 3-kinase-LY294002.
(B) Inhibition of PLK1 by wortmannin in an in vitro kinase assay. A nonradioactive PLK1 assay was used (Clyclex Polo-like kinase 1 Assay/
Inhibitor Screening Kit). The kit uses recombinant Protein-X as a substrate containing threonine residues that can be efficiently phosphory-
lated by PLK1. The amount of phosphorylated substrate is measured by using an anti-phospho-threonine polyclonal antibody (PPT-07),
followed by binding with horseradish peroxidase-conjugated anti-rabbit IgG, which then catalyzes the conversion of the chromogenic sub-
strate tetra-methylbenzidine (TMB) from a colorless solution to a blue solution. The blue solution changes to yellow after the addition of
stopping solution. The color is quantitated by spectrophotometry and reflects the relative amount of PLK1 activity. Briefly, 50 M ATP,
wortmannin at indicated concentrations, and 3 mU GST-tagged PLK1 in kinase buffer were added to a plate precoated with recombinant
Protein-X in a final volume of 100 l, and the plate was incubated for 30 min at 30°C. ATP minus control and no enzyme control were included
for every experiment.1/S-arrested cells. In contrast to PLK1, PI 3-kinases
nd DNA-PKcs expression were not changed in G1/S-
r G2/M-arrested Jurkat cells (Figure 5A). Western blot
nalysis confirmed the upregulation and downregula-
ion of PLK1 expression in G2/M- and G1/S-arrested
ells, respectively (Figure 5B). These results indicated
hat AX7503 could be used to monitor the changes in
LK1 expression during the cell cycle.
Since wortmannin is widely used to experimentally
nhibit PI 3-kinases, it was of interest to determine the
mount of PLK1 inhibition that results from treating live
ells with wortmannin. Intact G2/M-arrested Jurkat
ells were treated with a range of concentrations of
ortmannin for 30 min. After 30 min, cells were col-
ected, washed, and lysed. AX7503 treatment of these
ysates could then be used to assay for the inhibition
f its targets by wortmannin treatment of whole cells.
s shown in Figure 5C, treatment of the G2/M-arrested
urkat cells with wortmannin led to a decrease in the
ctivity of PI 3-kinases and PLK1. While wortmannin
nhibited PI 3-kinases more potently than PLK1, wort-
annin significantly inhibited PLK1 at concentrations
bove 25 nM (Figure 5C). For example, a 37% decrease
n PLK1 activity was observed when the G2/M-arrested
ells were treated with wortmannin at 100 nM. Western
lot analysis with a monoclonal PLK1 antibody con-
irmed that the expression of PLK1 did not change
pon treating cells with wortmannin (data not shown).
hese results indicated that, at the wortmannin con-
entrations used to inhibit PI 3-kinases in cell-based
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(A) AX7503 detects the upregulation of PLK1 expression in G2/M-
arrested Jurkat T cells. Jurkat cells were treated with 3 mM hy-
droxyurea for 16 hr (G1/S arrest), 10 M nocodzole for 15 hr (G2/M
arrest), or control DMSO, and soluble proteome (1.5 mg/ml) derived
from these cells was treated with AX7503 (50 nM) for 60 min. Reac-
tions were quenched with standard 2× SDS/PAGE loading buffer
(reducing), separated by SDS/PAGE, and visualized in-gel with a
flatbed laser-induced fluorescence scanner (MiraBio).
(B) The scanned gel from (A) was transferred to nitrocellulose and
immunoblotted with anti-PLK1.
(C) Jurkat cells were first treated with 10 M nocodazole for 15
hr (G2/M arrest). The intact cells were then treated with indicated
concentrations of wortmannin or control DMSO for 30 min. Cells
were collected, washed, and lysed. Soluble proteome (1.5 mg/ml)
derived from these cells was treated with AX7503 (50 nM) for 60
min. Reactions were quenched with standard 2× SDS/PAGE load-
ing buffer (reducing), separated by SDS/PAGE, and visualized in-
gel with a flatbed laser-induced fluorescence scanner (MiraBio).assays (50–500 nM), PLK1 inhibition could be physio-
logically relevant. In addition, wortmannin is also used
to inhibit PI 3-kinase-related kinases such as ATM at
much higher concentrations (as high as 5 M) (see, for
example [23]). Because wortmannin inhibits PLK1 in in-
tact G2/M-arrested cells and PLK1 is essential for mi-
totic spindle assembly [6, 10], these results also indi-
cate that wortmannin should inhibit mitotic progression
through inhibition of PLK1.
AX7503 Detects Changes in PLK1 Expression
in Cells Treated with Drugs
Paclitaxel poisons microtubules by disrupting the dy-
namic equilibrium between soluble tubulin dimers and
their polymerized form and is a potent inhibitor of chro-
mosome replication. Thus, it prevents normal cell divi-
sion and arrests the cell cycle at M phase [47]. Since
PLK1 expression is high in the mitotic phase, PLK1 ex-
pression should be upregulated upon paclitaxel treat-
ment. To test this hypothesis, we treated Jurkat cells
with paclitaxel and, as expected, the AX7503-labeled
PLK1 was more abundant in the soluble fraction oftreated than untreated cells (Figure 6A). Western blot
analysis confirmed the upregulation of PLK1 expres-
sion in the paclitaxel-treated cells (data not shown). In
addition to poisoning microtubules, paclitaxel also in-
duces apoptosis. We therefore looked for PLK1 changes
upon treatment with other inducers of apoptosis, stau-
rosporine and camptothecin (CPT). In contrast to pacli-
taxel, staurosporine and CPT had little effect or weakly
decreased PLK1 expression levels (Figure 6A). These
results suggest that the differences in drug-dependent
PLK1 expression were caused by the efficiency of the
drugs to trigger the mitotic checkpoint. The mitotic
spindle-destroying drug paclitaxel might induce apo-
ptosis through genes that regulate and control the spin-
dle assembly checkpoint of mitosis.
Paclitaxel is one of the major drugs used in the treat-
ment of ovarian and breast cancer. In order to deter-
mine whether paclitaxel also causes the upregulation
of PLK1 in cancer cells, we treated breast cancer line
MDA-MB-435 cells with paclitaxel as described in the
Experimental Procedures. As shown in Figure 6B, pacli-
taxel strongly induced the upregulation of PLK1 expres-
sion in MDA-MB-435 cells. These results indicate that
PLK1 expression, as determined by AX7503 labeling,
could serve as a biomarker for paclitaxel efficacy in
breast cancer treatment.
To test the ability of AX7503 to detect the upregula-
tion of PLK1 expression in cells treated with a drug that
drives cells into a state resembling mitosis, we treated
Jurkat cells with calyculin A, a serine/threonine phos-
phatase PP1 and PP2A inhibitor [48]. As shown in Fig-
ure 6C, AX7503 labeled more PLK1 in Jurkat cells
treated with calyculin A compared with control Jurkat
cells not treated with calyculin A. PLK1 expression, as
quantified by integrated fluorescent band intensity, was
2.3-fold higher in calyculin A-treated Jurkat cells rela-
tive to control Jurkat cells (Figure 6D). These results
indicate that PLK1 expression was dramatically increased
in calyculin A-stimulated cells and AX7503 could detect
these changes in PLK1 expression in crude cellular ex-
tracts. These results are consistent with previous re-
ports that calyculin A causes cells to arrest in G2/M.
The increased portion of cells in G2/M in the calyculin
A-treated cells presumably leads to increased levels of
PLK1. Collectively, these results highlight AX7503’s
ability to monitor the dynamics in PLK1 expression dur-
ing the cell cycle.
Due to its integrated fluorescent moiety and direct
1:1 labeling of its target, AX7503 may have utility in the
quantification of PLK1, which, as noted earlier, may be
a useful biomarker in oncology. Importantly, although
PLK1 is a possible target for treatment of cancer, very
few PLK1 inhibitors have been reported. One such in-
hibitor is scytonemin, which inhibits PLK1, as well as
other cell cycle regulatory kinases like Myt1, check-
point kinase 1, cyclin-dependent kinase 1/cyclin B, and
protein kinase Cβ2 in the low micromolar range [49].
Therefore, wortmannin may provide a valuable lead for
the development of PLK1 inhibitors.
The evidence that, in contrast to anti-PLK1 antibod-
ies, AX7503 is an activity-based probe for PLK1 fol-
lows. First, the labeling of PLK1 by AX7503 is blocked
by the small-molecule inhibitors wortmannin and
LY294002 and by heat denaturation. Second, AX7503
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Expression in Cells Treated with Drugs
(A) Jurkat cells were treated with 2 M pacli-
taxel for 20 hr, 1 M staurosporine for 2 hr, 3
M capmtothecin for 20 hr, or control DMSO,
and soluble proteome (1.5 mg/ml) derived
from these cells was treated with AX7503 (50
nM) for 60 min. Reactions were quenched
with standard 2× SDS/PAGE loading buffer
(reducing), separated by SDS/PAGE, and vis-
ualized in-gel with a flatbed laser-induced
fluorescence scanner (MiraBio).
(B) MDA-MB-435 cells were treated with 2 M
paclitaxel for 20 hr or control DMSO, and
soluble proteome derived from these cells
was treated with AX7503 (50 nM) for 60 min.
Reactions were quenched with standard 2×
SDS/PAGE loading buffer (reducing), sepa-
rated by SDS/PAGE, and visualized in-gel
with a flatbed laser-induced fluorescence
scanner (MiraBio).
(C) Jurkat cells were treated with 25 nM calyculin A or control DMSO for 30 min, and soluble proteome derived from these cells was treated
with AX7503 (50 nM) for 60 min. Reactions were quenched with standard 2× SDS/PAGE loading buffer (reducing), separated by SDS/PAGE,
and visualized in-gel with a flatbed laser-induced fluorescence scanner (MiraBio).
(D) Fluorescently labeled PLK1 was quantified by measuring integrated band intensities (normalized for volume).aexclusively reacts with the catalytically active form of
CPLK1. Furthermore, AX7503 can measure the increased
ror decreased total PLK1 activity resulting from changes
d
in expression in crude extracts. Finally, AX7503 inhibits i
PLK1 activity in vitro and covalently labels PLK1, fur- 1
wther supporting the notion that this tagged inhibitor re-
uacts with PLK1 in an activity-dependent manner.
o
fSignificance u
a
We report the synthesis and initial characterization of a
aAX7503, a wortmannin-based ABP that is able to dy-
Nnamically read out activity changes of a limited set of
Skinases within crude biological mixtures. We have pro-
T
vided examples of activity changes deriving from small- D
molecule inhibitor treatment of extracts or from changes a
hin protein expression in cells treated with drugs or syn-
schronized at stages of the cell cycle. Unexpectedly, we
sdiscovered that wortmannin potently inhibits PLK1 in
a
addition to the PI 3-kinase superfamily. Wortmannin’s p
potency for PLK1 is about 1000-fold higher than that of >
a previously published PLK inhibitor, scytonemin. Im- f
2portantly, we demonstrated that wortmannin potently
3inhibits PLK1 activity in vitro and also inhibits PLK1
(when added to live cells. At the concentrations of wort-
J
mannin commonly used to inhibit PI 3-kinases, PLK1 is (
also significantly inhibited. Wortmannin may be a valu- A
Table lead for the development of PLK1 inhibitors for
wcancer treatment, and AX7503 provides a unique se-
Dcondary screening method to analyze specificity of
r
PLK1 inhibitors, including wortmannin or LY294002 de- w
rivatives. i
m
Experimental Procedures p
f
Synthesis of AX7503 (
All solvents and reagents were obtained from the Aldrich Chemical 2
Company (Milwaukee, WI) unless otherwise indicated. The mixed 3
succinimidyl ester of 5-(and 6-)carboxytetramethylrhodamine H
((TAMRA-OSu) was obtained from Molecular Probes (Eugene, OR),nd wortmannin was obtained from A.G. Scientific, Inc. (San Diego,
A). Proton nuclear magnetic resonance (1H NMR) spectra were
ecorded on a Bruker 400 MHz NMR spectrometer in deuterated
imethylsulfoxide (d6-DMSO) using the residual solvent peak as the
nternal standard. LC/(ES)MS analysis was performed on an Agilent
100 Series LC/MSD with ChemStation software. Preparative HPLC
as carried out on a C18 reverse-phase column (Polaris, 5  col-
mn, 150 mm × 21 mm; Varian; Torrance, CA) using a binary system
f water and acetonitrile with 0.1% trifluoroacetic acid as a modi-
ier. Analytical LC/MS was carried out on a C18 reverse-phase col-
mn (Polaris, 5  column, 50 × 4.6 mm; Varian; Torrance, CA) using
binary system of water and acetonitrile with 0.1% trifluoroacetic
cid as a modifier. The purity of HPLC fractions was determined by
nalyzing the LC/MS trace at both 220 nm and 550 nm.
-(2-{2-[2-(2-TAMRA-Amino-Ethoxy)-Ethoxy]-Ethoxy}-Ethyl)-
uccinamic Acid [2]
o a solution of tetraethyleneglycol diamine (10.5 mg, 54.6 µmol) in
MF (280 µl) was added TAMRA-OSu (14.4 mg, 27.3 µmol) under
rgon. The solution was allowed to stir at room temperature for 1
r. Succinic anhydride (5.3 mg, 53.0 µmol) then was added to the
olution, followed by triethylamine (6.9 mg, 68.3 µmol). The reaction
olution was flushed with argon and allowed to stir at room temper-
ture for 23 hr. The reaction mixture was then purified by reverse-
hase chromatography. The fractions containing the product in
95% purity by HPLC were collected and lyophilized overnight, af-
ording compound 2 as a purple glass (11.9 mg, 62%). 1H NMR δ:
.30 (t, 2H, J = 6.8 Hz), 2.39 (t, 2H, J = 6.8 Hz), 3.11–3.30 (m, 12H),
.45–3.65 (m, 16H), 6.57 (b, 1H), 6.80–7.10 (b, 5H), 7.55 (b, 1H), 7.91
t, 1H, J = 5.2 Hz), 8.30 (d, 1H, J = 8.0 Hz), 8.67 (b, 1H), 8.97 (t, 1H,
= 4.4 Hz); ESMS: 705.0 [M + H]+, 353.0 [M + 2H]2+; MALDI-FTMS
DHB): m/z 705.3121 (C37H44N4O10 + H requires 705.3136).
X7503
o a solution of compound 2 (8 mg, 11 µmol) and 11-O-desacetyl-
ortmannin (1, 4.4 mg, 11.4 µmol) in CH2Cl2 (2.0 mL) was added
MAP (2 mg, 16 µmol), followed by DIC (6.75 µL, 43 µmol). The
eaction was stirred at ambient temperature for 16 hr. The solvent
as removed under vacuum, and the resulting solid was dissolved
n a minimal amount of DMSO and purified by reverse-phase chro-
atography. The fractions containing the product in >95% HPLC
urity were collected, and solvent was removed under vacuum, af-
ording AX7503 as a reddish glass (3.8 mg, 31%). 1H NMR δ: 1.23
s, 3H), 1.56 (dd, 2H, J = 10.8 Hz), 1.63 (s, 3H), 1.90–2.03 (m, 3H),
.17 (m, 2H), 2.26–2.47 (m, 4H), 3.06 (s, 3H), 3.15–3.28 (m, 12H),
.40–3.62 (m, 16H), 4.13 (dd, 2H, J= 3.4 Hz), 5.12 (dd, 1H, J = 1.6
z), 5.94 (m, 1H), 6.55 (b, 1H), 6.87–7.20 (b, 5H), 7.54 (b, 1H), 7.98
t, 1H, J = 5.2 Hz), 8.29 (d, 1H, J = 6.8 Hz), 8.67 (b, 1H), 8.94 (s,
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1051H), 8.95 (b, 1H); ESMS: 1073.4 [M + H]+; MALDI-FTMS (DHB): m/z
1073.4375 (C58H64N4O16 + H requires 1073.4396).
Cell Culture, Chemical Cell Cycle Synchronization,
and Inhibitor Treatment
Jurkat cells were grown in RPMI medium 1640 containing 10% fetal
calf serum (GIBCO-BRL, Invitrogen Corp.) in a humid atmosphere
of 5% CO2 at 37°C. The breast cancer lines MDA-MB-435, MDA-
MB-231, MCF-7, T-47D, and NCI/ADR were obtained from the Na-
tional Cancer Institute’s Developmental Therapeutics Program. All
breast cancer cell lines were grown to 80% confluence in RPMI
medium 1640 containing 10% fetal calf serum. For paclitaxel treat-
ment, MDA-MB-435 cells were grown to 80% confluence in RPMI
medium 1640 containing 10% fetal calf serum and were then
treated with paclitaxel. For drug-induced cell synchronization, Jur-
kat cells were treated with 3 mM hydroxyurea for 16 hr (G1/S arrest)
and 10 M nocodazole for 15 hr (G2/M arrest) [3]. For in vivo inhibi-
tion of PLK1 by wortmannin, Jurkat cells were first treated with
10 M nocodzole for 15 hr (G2/M arrest) and then treated with
wortmannin at the concentration indicated in the figure legends for
30 min. For inhibitor treatment, Jurkat cells were incubated in me-
dia containing calyculin A (25 nM), staurosporine (1 µM), paclitaxel
(2 µM), or camptothecin (3 µM) for the time indicated in the figure
legends [50–53]. Stock solutions of inhibitors were prepared in di-
methyl sulfoxide. Control incubations included the same amount of
dimethyl sulfoxide as the stock solutions.
Preparation of Cell Lysates
Cells were harvested by centrifugation and washed twice with cold
phosphate-buffered saline (pH 7.4). Cell pellets were briefly soni-
cated and Dounce homogenized in 50 mM HEPES (pH 7.4) contain-
ing 400 mM β-glycerol phosphate, 100 mM sodium pyrophosphate,
and 500 mM sodium sulfate (buffer 1). Cell extracts were centri-
fuged at 100,000 × g to provide soluble cellular proteome frac-
tions (supernatant).
Labeling of Protein Samples with AX7503
Soluble fractions were adjusted to a final protein concentration of
1.5 mg/ml in buffer 1 and treated with 50 nM AX7503 for 1 hr at
room temperature. Control reactions consisting of the soluble frac-
tions were preincubated with 0.5 M wortmannin or 50 M
LY294002 for 10 min prior to the addition of AX7503. Protein bands
that reacted with AX7503 in both preincubated and unpreincubated
samples with wortmannin or LY294002 were defined as nonspecific
labeling. Reactions were quenched with one volume of standard
2× SDS/PAGE loading buffer (reducing), separated by SDS/PAGE,
and visualized in-gel with a Hitachi FMBio IIe flatbed fluorescence
scanner (MiraiBio) as described [28, 36]. Fluorescently labeled
PLK1 and PI 3-kinases were quantified by measuring integrated
band intensities (normalized for volume). IC50 values were deter-
mined from dose-response curves with Prism software (GraphPad).
Isolation and Identification of AX7503-Labeled Proteins
AX7503-labeled proteins were isolated by using an immunoaffinity-
based purification procedure [54]. The enriched TAMRA-wortman-
nin-labeled proteins were separated by using SDS-PAGE, and the
protein bands were excised and digested with trypsin. The result-
ing peptides were analyzed by high-throughput microcapillary
reverse-phase chromatography (100 m capillary, 10 cm, C18) in
parallel with ion trap mass spectrometry (LCQ Deca XP, Thermofin-
nigan, San Jose, CA). Peptides were identified by using the Mascot
search algorithm and by de novo sequencing.
Polo-like Kinase 1 Activity Assay
An in vitro PLK1 assay in the presence and absence of various
inhibitors was performed by using the Clyclex Polo-like kinase 1
Assay/Inhibitor Screening Kit (CycLex Co., Ltd., Japan) according
to the manufacturer’s protocol, except that purified GST-tagged
PLK1 was diluted 60-fold into kinase buffer.
Western Blot Analysis
Quenched AX7503 reactions were run on SDS-PAGE (20 g/lane).
Proteins were then transferred by electroblotting onto nitrocellu-lose membranes (Protran). Western blot analysis with the anti-Polo-
like kinase mouse monoclonal antibody (Zymed, CA) was con-
ducted as described previously.
Expression of PLK1 in HEK-293 Cells
The HA-tagged PLK constructs, wild-type and the catalytically in-
active mutant K82R, and empty vector were transiently transfected
into HEK-293 cells by using methods described previously [44].
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